Brief report: A bioassay to identify primary human prostate cancer repopulating cells

Roxanne Toivanen, David Berman, Hong Wang, John S Pedersen, Mark Frydenberg, Alan Meeker, Stuart Ellem, Gail Risbridger, Renea Taylor

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Cancer cells are heterogeneous in both their phenotypes and ability to promote tumor growth and spread. Xenografting is used to identify the most highly capable cells to regenerating tumors, referred to as cancer repopulating cells. Because prostate cancers rarely grow as xenografts, indentifying prostate cancer repopulating cells has not been possible. Here we report improved methods to xenograft localized primary prostate cancer tissues using chimeric grafts with neonatal mouse mesenchyme. Xenograft survival of tumor tissue was significantly increased by neonatal mesenchyme (6/6 patients 66 of grafts vs 4/6 patients 41 of grafts) and doubled the proliferation index of xenografted cancer cells. When applied to isolated prostate cancer cells, neonatal mesenchyme effectively reconstituted prostate cancers and increased xenograft survival (4/9 patients; 32 of grafts with mesenchyme, 0 without), and supported active cancer cell proliferation. Using this assay, we showed that unfractionated alpha2beta1integrin(hi) and alpha2beta1integrin(lo) cells from primary localized prostate cancers demonstrated tumor formation at comparable rates, similar to previous reports using metastatic specimens. Thus, this new protocol efficiently established tumors and enabled proliferative expansion of both intact tumor tissue and fractionated cancer cells, providing a bioassay to identify and therapeutically target prostate cancer repopulating cells.
Original languageEnglish
Pages (from-to)1310 - 1314
Number of pages5
JournalStem Cells
Volume29
Issue number8
DOIs
Publication statusPublished - 2011

Cite this

@article{d0f97f60303b4a17819a0deb8b74a3b7,
title = "Brief report: A bioassay to identify primary human prostate cancer repopulating cells",
abstract = "Cancer cells are heterogeneous in both their phenotypes and ability to promote tumor growth and spread. Xenografting is used to identify the most highly capable cells to regenerating tumors, referred to as cancer repopulating cells. Because prostate cancers rarely grow as xenografts, indentifying prostate cancer repopulating cells has not been possible. Here we report improved methods to xenograft localized primary prostate cancer tissues using chimeric grafts with neonatal mouse mesenchyme. Xenograft survival of tumor tissue was significantly increased by neonatal mesenchyme (6/6 patients 66 of grafts vs 4/6 patients 41 of grafts) and doubled the proliferation index of xenografted cancer cells. When applied to isolated prostate cancer cells, neonatal mesenchyme effectively reconstituted prostate cancers and increased xenograft survival (4/9 patients; 32 of grafts with mesenchyme, 0 without), and supported active cancer cell proliferation. Using this assay, we showed that unfractionated alpha2beta1integrin(hi) and alpha2beta1integrin(lo) cells from primary localized prostate cancers demonstrated tumor formation at comparable rates, similar to previous reports using metastatic specimens. Thus, this new protocol efficiently established tumors and enabled proliferative expansion of both intact tumor tissue and fractionated cancer cells, providing a bioassay to identify and therapeutically target prostate cancer repopulating cells.",
author = "Roxanne Toivanen and David Berman and Hong Wang and Pedersen, {John S} and Mark Frydenberg and Alan Meeker and Stuart Ellem and Gail Risbridger and Renea Taylor",
year = "2011",
doi = "10.1002/stem.668",
language = "English",
volume = "29",
pages = "1310 -- 1314",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press, Inc",
number = "8",

}

Brief report: A bioassay to identify primary human prostate cancer repopulating cells. / Toivanen, Roxanne; Berman, David; Wang, Hong; Pedersen, John S; Frydenberg, Mark; Meeker, Alan; Ellem, Stuart; Risbridger, Gail; Taylor, Renea.

In: Stem Cells, Vol. 29, No. 8, 2011, p. 1310 - 1314.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Brief report: A bioassay to identify primary human prostate cancer repopulating cells

AU - Toivanen, Roxanne

AU - Berman, David

AU - Wang, Hong

AU - Pedersen, John S

AU - Frydenberg, Mark

AU - Meeker, Alan

AU - Ellem, Stuart

AU - Risbridger, Gail

AU - Taylor, Renea

PY - 2011

Y1 - 2011

N2 - Cancer cells are heterogeneous in both their phenotypes and ability to promote tumor growth and spread. Xenografting is used to identify the most highly capable cells to regenerating tumors, referred to as cancer repopulating cells. Because prostate cancers rarely grow as xenografts, indentifying prostate cancer repopulating cells has not been possible. Here we report improved methods to xenograft localized primary prostate cancer tissues using chimeric grafts with neonatal mouse mesenchyme. Xenograft survival of tumor tissue was significantly increased by neonatal mesenchyme (6/6 patients 66 of grafts vs 4/6 patients 41 of grafts) and doubled the proliferation index of xenografted cancer cells. When applied to isolated prostate cancer cells, neonatal mesenchyme effectively reconstituted prostate cancers and increased xenograft survival (4/9 patients; 32 of grafts with mesenchyme, 0 without), and supported active cancer cell proliferation. Using this assay, we showed that unfractionated alpha2beta1integrin(hi) and alpha2beta1integrin(lo) cells from primary localized prostate cancers demonstrated tumor formation at comparable rates, similar to previous reports using metastatic specimens. Thus, this new protocol efficiently established tumors and enabled proliferative expansion of both intact tumor tissue and fractionated cancer cells, providing a bioassay to identify and therapeutically target prostate cancer repopulating cells.

AB - Cancer cells are heterogeneous in both their phenotypes and ability to promote tumor growth and spread. Xenografting is used to identify the most highly capable cells to regenerating tumors, referred to as cancer repopulating cells. Because prostate cancers rarely grow as xenografts, indentifying prostate cancer repopulating cells has not been possible. Here we report improved methods to xenograft localized primary prostate cancer tissues using chimeric grafts with neonatal mouse mesenchyme. Xenograft survival of tumor tissue was significantly increased by neonatal mesenchyme (6/6 patients 66 of grafts vs 4/6 patients 41 of grafts) and doubled the proliferation index of xenografted cancer cells. When applied to isolated prostate cancer cells, neonatal mesenchyme effectively reconstituted prostate cancers and increased xenograft survival (4/9 patients; 32 of grafts with mesenchyme, 0 without), and supported active cancer cell proliferation. Using this assay, we showed that unfractionated alpha2beta1integrin(hi) and alpha2beta1integrin(lo) cells from primary localized prostate cancers demonstrated tumor formation at comparable rates, similar to previous reports using metastatic specimens. Thus, this new protocol efficiently established tumors and enabled proliferative expansion of both intact tumor tissue and fractionated cancer cells, providing a bioassay to identify and therapeutically target prostate cancer repopulating cells.

UR - http://onlinelibrary.wiley.com/doi/10.1002/stem.668/pdf

U2 - 10.1002/stem.668

DO - 10.1002/stem.668

M3 - Article

VL - 29

SP - 1310

EP - 1314

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 8

ER -